Instinct Bio Technical Company Holdings Inc. received notifications from Nasdaq on September 9 and 10, 2026, indicating non-compliance with three continued listing requirements for the Nasdaq Global Market. The company failed to maintain a minimum market value of listed securities (MVLS) of $50 million, a minimum market value of publicly held shares (MVPHS) of $15 million, and a minimum bid price of $1.00 per share during periods ending in early September 2026. Nasdaq granted the company an 180-day compliance period until March 8 or 9, 2027, to regain compliance by meeting these thresholds for ten consecutive business days. Failure to comply may result in delisting proceedings, though the company may appeal or transfer to the Nasdaq Capital Market. The company is evaluating options to cure these deficiencies and has no guarantee of success. Instinct Bio Technical Company Holdings Inc. operates in the biotechnology industry, focusing on regenerative medicine, wellness technologies, and therapeutic platform development.

Instinct Bio Technical Company Holdings Inc. announced a cooperation agreement with PT Parva Candela on August 10, 2026, to jointly develop Indonesia’s cosmetics and personal care market. The partnership leverages PT Parva Candela's manufacturing facility and distribution network through its affiliated DELTASPA Group spa chain. Instinct Bio will provide proprietary formulations under the GENRÊVER and HAKUA brands, retaining intellectual property ownership while granting limited licenses. Revenue streams include a 50% profit share, ingredient supply fees, formulation royalties, and brand licensing. This initiative follows previous strategic announcements regarding an integrated clinic and a collaboration with Invitrx Therapeutics. Instinct Bio operates in the regenerative medicine, cosmetics, wellness, and consumer brands industry.

On July 30, 2026, Instinct Bio Technical Company Holdings Inc. announced a strategic collaboration with Invitrx Therapeutics, Inc., to expand its GENRÊVER cosmetic brand into the United States and explore regenerative medicine opportunities in Indonesia. The partnership leverages Instinct Bio's proprietary formulations and Invitrx's U.S. GMP manufacturing capabilities for product commercialization, while also evaluating the supply of concentrated exosomes and conditioned media for Indonesian clinics. This framework builds upon a six-year existing commercial relationship between the parties. As a biotechnology company focused on regenerative medicine, longevity-related technologies, and advanced therapeutic platforms, Instinct Bio aims to strengthen its international growth through these new market entries.

Instinct Bio announced an agreement with Dr. Mario Damianus Daniel Hadinoto to launch its Japanese aesthetic brand, GENRÊVER CLINIC, in Indonesia via a subscription-model membership beauty clinic business. The company plans an initial investment of approximately US$1 million to establish five directly operated clinics in major metropolitan areas including Jakarta, Surabaya, Bandung, Medan, and Bali. This initiative aims to create a recurring-revenue platform with transparent pricing and flexible cancellation terms, serving as a strategic gateway to the Company’s core regenerative medicine business involving stem-cell and iPS-cell technologies. Instinct Bio is a biotechnology company focused on regenerative medicine, longevity-related technologies, and advanced therapeutic platforms.

Instinct Bio Technical Company Holdings Inc. announced on July 28, 2026, that it has entered into an indicative term sheet for a proposed equity purchase facility allowing the sale of up to US$150 million of common stock over three years. The facility provides the company with the right, but not the obligation, to direct share purchases based on volume-weighted average price less a specified discount. Proceeds are intended to accelerate the development of its regenerative medicine platform, fund working capital, and pursue strategic acquisitions. This transaction is not yet finalized and depends on executing definitive documents and satisfying conditions. Instinct Bio is a biotechnology company focused on regenerative medicine, longevity-related technologies, and advanced therapeutic platforms.